Alteration in serum and bone component findings induced in streptozotocin-diabetic rats is restored by zinc acexamate

  • Authors:
    • Satoshi Uchiyama
    • Masayoshi Yamaguchi
  • View Affiliations

  • Published online on: December 1, 2003     https://doi.org/10.3892/ijmm.12.6.949
  • Pages: 949-954
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The effect of zinc acexamate in streptozotocin (STZ)-induced diabetic rats was investigated. Rats received a single subcutaneous administration of STZ (6.0 mg/100 g body weight), and the animals were orally administered once daily for 14 days with zinc acexamate (2.5, 5 or 10 mg/100 g body weight). The administration of STZ caused a significant increase in serum glucose, triglyceride and calcium levels and a significant decrease in body weight, serum zinc and inorganic phosphorus levels, indicating diabetic condition. Moreover, calcium content, alkaline phosphatase activity and deoxyribonucleic acid (DNA) content in the femoral-diaphyseal and -metaphyseal tissues were significantly reduced in STZ-diabetic rats. The change in these serum and bone components of STZ-diabetic rats was significantly restored by the oral administration of zinc acexamate (2.5, 5 or 10 mg Zn/100 g body weight). The restoration of bone components was not seen by the oral administration of zinc sulfate (2.5 mg Zn/100 g) for 14 days. Moreover, when the femoral-diaphyseal and -metaphyseal tissues obtained at 14 days after STZ administration were cultured for 48 h in a medium containing either vehicle or zinc acexamate (10−5 M), the femoral calcium content and alkaline phosphatase activity were significantly increased in vitro. The effet of zinc acexamate was completely abolished in the presence of cycloheximide (10−6 M), an inhibitor of protein synthesis. The present study demonstrates that the oral administration of zinc acexamate has a preventive effect on STZ-induced diabetic condition in rats, and that it can restorate bone loss of STZ-induced diabetes in vivo.

Related Articles

Journal Cover

December 2003
Volume 12 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Uchiyama S and Yamaguchi M: Alteration in serum and bone component findings induced in streptozotocin-diabetic rats is restored by zinc acexamate. Int J Mol Med 12: 949-954, 2003.
APA
Uchiyama, S., & Yamaguchi, M. (2003). Alteration in serum and bone component findings induced in streptozotocin-diabetic rats is restored by zinc acexamate. International Journal of Molecular Medicine, 12, 949-954. https://doi.org/10.3892/ijmm.12.6.949
MLA
Uchiyama, S., Yamaguchi, M."Alteration in serum and bone component findings induced in streptozotocin-diabetic rats is restored by zinc acexamate". International Journal of Molecular Medicine 12.6 (2003): 949-954.
Chicago
Uchiyama, S., Yamaguchi, M."Alteration in serum and bone component findings induced in streptozotocin-diabetic rats is restored by zinc acexamate". International Journal of Molecular Medicine 12, no. 6 (2003): 949-954. https://doi.org/10.3892/ijmm.12.6.949